Table 1.
Findings From Clinical, Laboratory, and Imaging Examinations
|
All patients n=37 |
AL n=19 (51%) |
ATTR n=18 (49%) |
P Value | |
|---|---|---|---|---|
| Men, n (%) | 34 (92) | 17 (90) | 17 (94) | 0.580 |
| Age, years, interquartile range | 72 (68–81) | 69 (67–74) | 76 (70–83) | 0.024 |
| eGFR, mL/min per 1.73 m2 | 67 (45–79) | 61 (42–79) | 71 (55–79) | 0.199 |
| NYHA class I–II/III–IV, n (%) | 15/22 (41/59) | 7/12 (37/63) | 8/10 (44/56) | 0.638 |
| Hematocrit (%) | 36 (34–40) | 36 (34–40) | 36 (35–40) | 0.897 |
| NT‐proBNP, ng/L | 6772 (2071–12 557) | 10 164 (1912–16 874) | 3750 (2361–8592) | 0.118 |
| hs‐TnT, ng/L | 62 (38–140) | 95 (37–207) | 54 (38–93) | 0.134 |
| sST2, ng/mL | 27 (16–37) | 21 (14–32) | 32 (21–45) | 0.167 |
| TTE | ||||
| E/e′ | 17 (12–24) | 15 (12–25) | 18 (12–23) | 0.916 |
| LAVi, mL/m2 | 24 (21–28) | 24 (21–28) | 25 (20–29) | 0.618 |
| Moderate/severe aortic stenosis | 2 (5) | 1 (5) | 1 (6) | 0.969 |
| TAPSE | 17 (13–22) | 17 (14–24) | 16 (13–22) | 0.586 |
| CMR | ||||
| LVEDVi, mL/m2 | 79 (68–92) | 78 (62–90) | 80 (73–94) | 0.374 |
| LVESVi, mL/m2 | 32 (28–43) | 32 (23–45) | 32 (30–40) | 0.531 |
| SVi, mL/m2 | 42 (32–51) | 38 (28–49) | 46 (36–55) | 0.232 |
| LVEF (%) | 54 (45–62) | 52 (45–56) | 58 (42–63) | 0.449 |
| LVMI, g/m2 | 112 (102–143) | 109 (91–115) | 140 (110–153) | 0.022 |
| IVS, mm | 19 (17–21) | 18 (15–21) | 20 (17–22) | 0.199 |
| PW, mm | 15 (12–16) | 15 (12–19) | 15 (12–16) | 0.880 |
| RVEDVi, mL/m2 | 76 (65–92) | 77 (65–89) | 71 (65–98) | 0.746 |
| RVEF, % | 55 (44–64) | 51 (43–63) | 55 (45–67) | 0.589 |
| Small LGE areas, n (%) | 4/28 (14) | 3/15 (20) | 1/13 (8) | 0.594 |
| Subendocardial LGE, n (%) | 9/28 (32) | 5/15 (33) | 4/13 (31) | |
| Transmural LGE, n (%) | 15/28 (54) | 7/15 (47) | 8/13 (61) | |
| LGE score | 10 (7–13) | 10 (6–14) | 10 (8–13) | 1.000 |
| Blood‐pool early darkening, n (%) | 10/28 (36) | 8/15 (53) | 2/13 (15) | 0.055 |
| Native myocardial T1, ms † | 1118 (1016–1196) | 1191 (1118–1229) | 1015 (972–1070) | 0.036 |
| ECV (%) † | 54 (44–61) | 54 (45–59) | 54 (42–69) | 0.972 |
| Pericardial effusion, n (%) | 9/29 (31) | 7/16 (44) | 2/13 (15) | 0.130 |
| Pleural effusion, n (%) | 9/29 (31) | 5/16 (31) | 4/13 (31) | 1.000 |
The interquartile interval was reported in parentheses.
AL indicates amyloid light‐chain amyloidosis; ATTR, amyloid transthyretin amyloidosis; CMR, cardiac magnetic resonance; ECV, extracellular volume; eGFR, estimated glomerular filtration rate; hs‐TnT, high‐sensitivity troponin T; IVS, interventricular septum; LAVi, left atrial volume index; LGE, late gadolinium enhancement; LVEDVi, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end‐systolic volume index; LVMI, left ventricular mass index; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PW, posterior wall thickness; RVEDVi, right ventricular end‐diastolic volume index; RVEF, right ventricular ejection fraction; sST2, soluble suppression of tumorigenesis‐2; SVi, stroke volume index; TAPSE, tricuspid annular plane systolic excursion; and TTE, transthoracic echocardiography.
Myocardial T1, ECV, matrix volume, and cell volume were available only in 20 subjects.